Meet John de Groot, M.D.
John F. de Groot, M.D.
Department of Neuro-Oncology, Division of Cancer Medicine
About Dr. de Groot
Dr. John de Groot is a Professor, and Chairman ad interim, in the Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center. He is an expert in the fields of glioma angiogenesis and molecularly targeted therapy. He completed his medical education at The University of Texas Medical Branch at Galveston, and pursued internship and residency at Johns Hopkins School of Medicine. Following a clinical fellowship at MD Anderson, de Groot joined the faculty in 2004. His translational research program has produced critical insights into how gliomas respond to and resist killing by anti-angiogenic agents and illuminated therapeutic approaches employed in clinical trials to overcome this resistance. De Groot has also significantly contributed to the discovery of biomarkers of response and progression in glioblastoma patients treated with anti-angiogenic therapy, and as a result has opened multiple biomarker-driven clinical trials.
Dr. de Groot has served as the principal investigator (PI) or co-investigator on multiple funded National Cancer Institute, foundation, and industry-sponsored grants. He is the PI of numerous clinical trials involving novel agents being tested in patients with glioblastoma and is a co-leader of the MD Anderson GBM Moon Shot program. Dr. de Groot has over 123 peer-reviewed articles. He is or has served as a peer reviewer for 23 scientific journals and is on our editorial review boards. As director of the Neuro-Oncology Fellowship Program, he has direct influence on the teaching of the next generation of clinician scientists.
Present Title & Affiliation
Primary Appointment
Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Department Chair ad interim, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1998 | The University of Texas Medical Branch at Galveston, Galveston, TX, USA, MD, Medicine |
| 1992 | Stanford University, Stanford, USA, BA, Human Biology |
Postgraduate Training
| 2002-2004 | Clinical Fellowship, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1999-2002 | Clinical Residency, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD |
| 1998-1999 | Clinical Internship, Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD |
Board Certifications
| 2013 | United Council for Neurologic Subspecialties (UCNS) - Neuro-Oncology |
| 2002 | American Board of Psychiatry and Neurology |
Experience & Service
Institutional Committee Activities
Member, Graduate Medical Education (GME) Committee, 2008 - 2017
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer 112:83-93, 2019. e-Pub 2019. PMID: 30951926.
- Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med:477-486, 2019. e-Pub 2019. PMID: 30742122.
- Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol:741-750, 2019. e-Pub 2019. PMID: 30715997.
- Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer 125(3):424-433, 2019. e-Pub 2018. PMID: 30359477.
- Pascal ZO, Singh SK, Aikaternini K, Islam H, Thomas G, Luedi MM, Elakkad A, Elshafeey N, Tagwa I, Mosley J, Gumin J, Fuller GN, de Groot JF, Baladandayuthapani V, Suman EP, Kumar AJ, Sawaya R, Lang FF, Piwnica-Worms D, Colen RR. A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. Clin Cancer Res 24(24):6288-6299, 2018.
- Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer 143(11):3019-3026, 2018. e-Pub 2018. PMID: 29923182.
- Schiff D, de Groot JF. Lower-grade gliomas: the wrong target for bevacizumab. Neuro Oncol 20(12):1559-1560, 2018. PMID: 30418659.
- Harrison RA, de Groot JF. Treatment of Glioblastoma in the Elderly. Drugs Aging 35(8):707-718, 2018. PMID: 30039343.
- Daher A, de Groot J. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model. Exp Neurol 299(Pt B):281-288, 2018. e-Pub 2017. PMID: 28923369.
- Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47-62, 2018. e-Pub 2017. PMID: 28925994.
- Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clin Cancer Res:295-305, 2018. e-Pub 2017. PMID: 29074604.
- Piao Y, Henry V, Tiao N, Park SY, Martinez-Ledesma J, Dong JW, Balasubramaniyan V, de Groot JF. Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma. Oncotarget 8(57):96970-96983, 2017. e-Pub 2017. PMID: 29228586.
- Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res 23(19):5745-5756, 2017. e-Pub 2017. PMID: 28655794.
- Penas-Prado M, de Groot J. CATNON interim results: another triumph of upfront chemotherapy in glioma. Neuro Oncol 19(10):1287-1288, 2017. PMID: 28922864.
- Nam JY, de Groot JF. Treatment of Glioblastoma. J Oncol Pract 13(10):629-638, 2017. PMID: 29020535.
- Lee JH, Liu R, Li J, Zhang C, Wang Y, Cai Q, Qian X, Xia Y, Zheng Y, Piao Y, Chen Q, de Groot JF, Jiang T, Lu Z. Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. Nat Commun 8(1):949, 2017. e-Pub 2017. PMID: 29038421.
- Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP. A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. Oncotarget 8(52):90488-90495, 2017. e-Pub 2017. PMID: 29163847.
- Cachia D, Elshafeey NA, Kamiya-Matsuoka C, Hatami M, Alfaro-Munoz KD, Mandel JJ, Colen R, DeGroot JF. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. J Neurooncol 135(1):75-81, 2017. e-Pub 2017. PMID: 28702781.
- Harrison RA, de Groot JF. Cell Signaling Pathways in Brain Tumors. Top Magn Reson Imaging 26(1):15-26, 2017. PMID: 28079711.
- O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol 130(3):495-503, 2016. e-Pub 2016. PMID: 27576699.
- Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res 29(6):627-642, 2016. e-Pub 2016. PMID: 27615400.
- Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 18(10):1357-66, 2016. e-Pub 2016. PMID: 27370400.
- Park SY, Piao Y, Jeong KJ, Dong J, de Groot JF. Periostin (POSTN) regulates tumor resistance to antiangiogenic therapy in glioma models. Mol Cancer Ther 15(9):2187-97, 2016. e-Pub 2016. PMID: 27307601.
- Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro Oncol 18(9):1230-41, 2016. e-Pub 2016. PMID: 26965451.
- Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WK, de Groot JF. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol 129(3):487-94, 2016. e-Pub 2016. PMID: 27406589.
- Mandel JJ, Cachia D, Liu D, Wilson C, Aldape K, Fuller G, de Groot JF. Impact of IDH-1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol 129(1):147-54, 2016. e-Pub 2016. PMID: 27270908.
- Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. Prioritization Schema for Immunotherapy Clinical Trials in Glioblastoma. Oncoimmunology 5(6):e1145332, 2016. e-Pub 2016. PMID: 27471611.
- Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol 18(4):557-64, 2016. e-Pub 2015. PMID: 26449250.
- Gatson NT, Weathers SP, de Groot JF. ReACT Phase II Trial: A critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII positive recurrent glioblastoma. CNS Oncol 5(1):11-26, 2016. e-Pub 2015. PMID: 26670466.
- Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol 126(2):309-16, 2016. e-Pub 2015. PMID: 26508094.
- Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, Fuller GN, Gilbert MR, De Groot JF. Primary and Secondary Gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol 125(2):401-10, 2015. e-Pub 2015. PMID: 26354773.
- Liang J, Piao Y, Henry V, Tiao N, de Groot JF. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy. Oncotarget 6(31):31479-92, 2015. PMID: 26362401.
- Webre C, Shonka N, Smith L, Liu D, de Groot J. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. Anticancer Res 35(10):5467-72, 2015. PMID: 26408710.
- Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, de Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol 33(25):2753-2762, 2015. e-Pub 2015. PMID: 26014291.
- Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol 17(8):1051-63, 2015. e-Pub 2015. PMID: 25934816.
- Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clin Chem 61(3):544-53, 2015. e-Pub 2015. PMID: 25626406.
- Martinez-Ledesma E, de Groot JF, Verhaak RG. Seek and destroy: relating cancer drivers to therapies. Cancer Cell 27(3):319-21, 2015. PMID: 25759016.
- Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program, Brain Tumor Trials Collaborative. Randomized Phase II Adjuvant Factorial Study of Dose-dense Temozolomide Alone and in Combination with Isotretinoin, Celecoxib, and/or Thalidomide for Glioblastoma. Neuro Oncol 17(2):266-73, 2015. e-Pub 2014. PMID: 25239666.
- Mella DB, Kamiya-Matsuoka C, Liao B, Tummala S, de Groot J. Recurrent encephaloclastic cyst induced by intraventricular topotecan. J Neurol Sci 349(1-2):52-3, 2015. e-Pub 2014. PMID: 25598491.
- Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol 17(2):180-8, 2015. e-Pub 2014. PMID: 25165194.
- Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD, Bruner JM, Puduvalli VK. Adult brainstem gliomas: Correlation of clinical and molecular features. J Neurol Sci 353(1-2):92-7, 2015. e-Pub 2015. PMID: 25934342.
- Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res 20(22):5612-9, 2014. PMID: 25398844.
- Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS. Pregnancy and glial brain tumors. Neuro Oncol 16(9):1289-94, 2014. e-Pub 2014. PMID: 24615863.
- Weathers SP, de Groot J. Resistance to antiangiogenic therapy. Curr Neurol Neurosci Rep 14(5):443, 2014. PMID: 24652451.
- Chen SE, Choi SS, Rogers JE, Lei X, de Groot JF. Isotretinoin Maintenance Therapy for Glioblastoma: A Retrospective Review. J Oncol Pharm Pract 20(2):112-9, 2014. e-Pub 2013. PMID: 23676507.
- de Groot JF, Mandel JJ. Update on Anti-angiogenic Treatment for Malignant Gliomas. Curr Oncol Rep 16(4):380, 2014. PMID: 24510742.
- Yust-Katz S, Anderson MD, Liu D, Wu J, Yuan Y, Olar A, Fuller GN, Brown PD, de Groot JF. Clinical and prognostic features of adult patients with gangliogliomas. Neuro Oncol 16(3):409-13, 2014. e-Pub 2013. PMID: 24305706.
- Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, de Groot JF. Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res 20(1):187-98, 2014. e-Pub 2013. PMID: 24240114.
- Barney CL, Brown AP, Grosshans DR, McAleer MF, de Groot JF, Puduvalli V, Tucker SL, Crawford CN, Gilbert MR, Brown PD, Mahajan A. Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation. Neuro Oncol 16(2):303-9, 2014. e-Pub 2013. PMID: 24311638.
- Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One 9(3):e91216, 2014. e-Pub 2014. PMID: 24614622.
- Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition. Clin Cancer Res 19(16):4392-403, 2013. e-Pub 2013. PMID: 23804423.
- Shonka N, Piao Y, Gilbert M, Yung WKA, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot JF. Cytokines associated with toxicity in treatment of recurrent Glioblastoma with Aflibercept. Target Oncology 8(2):117-125, 2013. e-Pub 2013. PMID: 23345034.
- Brown AP, Barney CL, Grosshans DR, McAleer MF, de Groot JF, Puduvalli VK, Tucker SL, Crawford CN, Khan M, Khatua S, Gilbert MR, Brown PD, Mahajan A. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys 86(2):277-84, 2013. e-Pub 2013. PMID: 23433794.
- Kamiya-Matsuoka C, Garciarena P, Hesham MA, Tremont I, de Groot JF. B Lymphoblastic Leukemia/Lymphoma Presenting As Seventh Cranial Nerve Palsy. Neurology, 2013.
- Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF. Glioblastoma Resistance to Anti-VEGF Therapy is Associated with Myeloid Cell Infiltration, Stem Cell Accumulation, and a Mesenchymal Phenotype. Neuro Oncol 14(11):1379-1392, 2012. e-Pub 2012. PMID: 22965162.
- Theeler BJ, Yung WK, Fuller GN, de Groot JF. Moving Toward Molecular Classification of Diffuse Gliomas in Adults. Neurology 79(18):1917-1926, 2012. PMID: 23109653.
- Walker GV, Li J, Mahajan A, McAleer MF, de Groot JF, Azeem SS, Brown PD. Decreasing radiation therapy utilization in adult patients with glioblastoma multiforme: A population-based analysis. Cancer 118(18):4538-44, 2012. e-Pub 2012. PMID: 22359097.
- de Groot JF, Liang J, Kong LK, Wei J, Piao Y, Fuller G, Qiao W, Hemberger AB. Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator Transcription 3 Pathway in Glioblastoma. Oncotarget 9(3):1036-48, 2012. PMID: 23013619.
- Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, de Groot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. J Clin Oncol 28(11):1963-72, 2010. e-Pub 2010. PMID: 20231676.
- Ahluwalia MS, de Groot J, Liu W, Gladson CL. Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies. Cancer Letters 298(2):139-49, 2010. PMID: 20947248.
- Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy. Clin Cancer Res 15(14):4589-99, 2009. PMID: 19567589.
- Piao Y, Lu L, de Groot J. AMPA receptors promote perivascular glioma invasion via (beta) 1 integrin-dependent adhesion to the extracellular matrix. Neuro-Oncology 11(3):260-73, 2009. PMID: 18957620.
- Milano V, Piao Y, Lafortune T, de Groot J. Desatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Molecular Cancer Therapy 8(2):394-406, 2009. PMID: 19190119.
- Gonzales J, de Groot J. Combination therapy for malignant glioma based on PTEN status. Expert Rev Anticancer Therapy 8(11):1767-1779, 2008. PMID: 18983237.
- de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neuro-Oncology 90(1):89-97, 2008. PMID: 18581057.
- Gomez-Manzano C, Holash J, Fueyo J, Xu Jing, Conrad, CA, Aldape KD, de Groot JF, Bekele N, Yung WKA. VEGF Trap induces antiglioma effect at different stages of disease. Neuro-Oncology 10(6):940-945, 2008. PMID: 18708344.
- de Groot J, Yung, WKA. Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas. Cancer J 14(5):279-285, 2008. PMID: 18836331.
- de Groot JF, Liu TJ, Fuller G, Yung WK. The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res 65(5):1934-40, 2005. PMID: 15753393.
- Grossman KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, de Groot JF, Aiken RD, Olsen JJ, Evans BA, Jensen RL. Phase I Trial of Verubulin (MPC-6827) plus carboplatin in Patients with Relapsed Glioblastoma Multiforme. Journal of Neuro Oncology. e-Pub 2012. PMID: 22932984.
- Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WKA. A Phase I Factorial Design Study of Dose-Dense Temozolomide Alone and in Combination with Thalidomide, Isotretinoin, and/or Celecoib as Postchemoradiation Adjuvant Therapy for Newly Diagnosed Glioblastoma. Neuro-Oncology 12(11):1167-72. e-Pub 2010. PMID: 20729242.
- Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Invest New Drugs. e-Pub 2014. PMID: 25388940.
- Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol:JCO2016715292. e-Pub 2017. PMID: 28148207.
- Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. e-Pub 2017. PMID: 28116649.
- Park SY, Piao Y, Thomas C, Fuller GN, de Groot JF. Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma. Oncotarget. e-Pub 2016. PMID: 27050366.
- Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, de Groot J, Aldape K, Gilbert MR, Brain Tumor Trials Collaborative. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol. e-Pub 2015. PMID: 26476729.
- Ludmir EB, Mandel JJ, McAleer MF, de Groot JF. Disparities along the glioblastoma clinical trials landscape. Neuro Oncol. e-Pub 2018. PMID: 30476295.
- Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Brachman D, Jenrette JM, De Groot J, Bovi JA, Werner-Wasik M, Knisely JPS, Mehta MP. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg:1-13. e-Pub 2017. PMID: 28984517.
- Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. e-Pub 2017. PMID: 29036345.
Book Chapters
- de Groot JF, Yung, WK. Small Molecule Based Therapies. In Neuro-Oncology. In: Neuro-Oncology: The Essentials. 2nd. Thieme Publishers: New York, NY, 234-241, 2008.
Grant & Contract Support
| Title: | ImaRx Therapeutics Investigator Initiated Study "Enhancing drug delivery using ultrasound plus nanobubbles" |
| Funding Source: | ImaRX |
| Role: | Principal Investigator |
| Title: | Glutamate excitotoxicity, cystine and glioma growth |
| Funding Source: | American Brain Tumor Association (ABTA) - Basic Research Fellowship |
| Role: | Investigator |
| Title: | Deciphering Synergistic Combinatorial Targets in Glioma |
| Funding Source: | NIH/NCI/NINDS |
| Role: | Co-Investigator |
| Title: | Correlative Markers of Glioblastoma Response to VEGF Trap |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | The Role of AMPA Receptors in Glioma Proliferation and Invasion |
| Funding Source: | UTMDACC Institutional Research Grant-IRG |
| Role: | Principal Investigator |
| Title: | Predictors of Glioblastoma Response to VEGF Trap |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | SPORE in Brain Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | The effect of CT-322 on glioma biology and growth in an in vivo glioma stem cell model |
| Funding Source: | Adnexus |
| Role: | Principal Investigator |
| Title: | Preclinical Validation of Targeting Macrophage CSF-1R in Glioblastoma |
| Funding Source: | AstraZeneca Research Collaboration Alliance |
| Role: | Principal Investigator |
| Title: | Ivy CTC Virtual Tissue Bank for Malignant Glioma Patients |
| Funding Source: | The Ben and Catherine Ivy Foundation |
| Role: | Principal Investigator |
| Title: | Modulation of Resistance to Antiangiogenic Therapy: A Clinical Trial with Correlative Studies |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Preclinical Validation of Targeting the JAK/STAT Pathway in Glioma with AZD1480 |
| Funding Source: | AstraZeneca |
| Role: | Investigator |
| Title: | SPORE DRP- Targeting the JAK2/STAT-3 Pathway in Glioma to Overcome Resistance to Antiangiogenic Therapy |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| Title: | Evaluation of XL765 for the Prevention of Glioblastoma Resistance to Bevacizumab Therapy |
| Funding Source: | Sanofi-Aventis |
| Role: | Principal Investigator |
| Title: | Preclinical Validation of Targeting P70S6K/AKT with MSC3318 |
| Funding Source: | EMD Serono |
| Role: | Principal Investigator |
| Title: | Molecular Predictors of Response to Targeted Therapy in Glioblastoma: Preclinical Validation of Eli Lilly Compounds Targeting CDK4/6, SHH, FGFR, cMET, and p38-MAPK |
| Funding Source: | Eli Lilly |
| Role: | Principal Investigator |
| Title: | Ivy CTC Virtual Tissue Bank for Malignant Glioma Patients |
| Funding Source: | Ivy Foundation Early Phase Clinical Trials Consortium |
| Role: | Principal Investigator-MDACC |
| Title: | Evaluation of Novartis oncology compounds to validate specific targeted therapies in glioblastoma with unique subtype and molecular profiles |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | SPORE for Brain Tumors: Animal Core (Core E) |
| Funding Source: | NIH/NCI |
| Role: | Co-Program Leader |
Dr. John de Groot is a neuro-oncologist specializing in the treatment of primary brain tumors, including glioblastoma.
Dr. John de Groot sees patients in the Brain and Spine Center at MD Anderson.
Dr. de Groot presents an update on his Brain Cancer SPORE grant project team's research.